When developing interventions to improve population health, particularly among minority groups, research must take a culturally sensitive approach that is targeted to the specific needs of that population, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities. He also emphasized the importance of clinicians’ role in population health.
When developing interventions to improve population health, particularly among minority groups, research must take a culturally sensitive approach that is targeted to the specific needs of that population, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities. He also emphasized the importance of clinicians’ role in population health.
Transcript (slightly modified)
What are some important considerations in designing health interventions for minority populations?
The 2 parts are, first of all, the attitude. I believe our attitude determines our altitude, how far we can go and how high we can go. It’s the recognition that all racial/ethnic minorities are different, all populations are different, and the first attitude must be that of humility, of really trying to understand the cultural aspects, the behavioral aspects, the determinants of population health.
Secondly, it’s some sort of ascertainment: compiling and knowing the epidemiology, the risk factors, the rates, which cancers and risk factors are the most prominent and what can be done about it. Then, to the extent possible, to design interventions that are culturally competent, meaning with the population, not on the population. That might mean training bilingual, bicultural individuals who can reach out to the community.
I think that conducting this, sustaining that, is the way to go. We’ve been able to show that it has worked. It’s more effective than, shall we say, just a missile approach or whatever.
What role can clinicians play in improving population health?
I want to reinforce how important, and never to underestimate, the provider’s influence on healthcare of the patient. The provider is the major gateway, decision maker, and trusted individual to do this, and so that’s a tremendous responsibility and obligation to do. I feel really privileged whenever I can to just reflect the research and the patient community on how important the provider’s role is.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More